Nektar Therapeutics股价下跌，陪审团在Nektar与礼来就Rezpeg专利纠纷中审议（NKTR:NASDAQ）
· seekingalpha.com
Nektar（NKTR）股价下跌11%，因陪审团在就Rezpeg药物与礼来的专利纠纷中进行审议。
Nektar Therapeutics (NKTR) quickly sank 11% as a jury deliberated in its patent dispute with Eli Lilly (LLY) over its Rezpeg drug.
The jury in San Francisco fe...